Boehringer Ingelheim India, Startup Incubation and Innovation Centre ink pact to support socially impactful innovations

In 2021, India reported 20 Lakh cases of tuberculosis, which accounts for around 27% of the global burden of the disease, according to the Ministry of Health and Family Welfare's annual TB report. With the rising burden of TB in the country, this partnership will enable Lenek technologies to expand its reach and continue to work toward eliminating tuberculosis and helping improve millions of lives.

"At Boehringer Ingelheim, we are committed to transforming lives with the help of innovation. The last three years have underlined the importance of technology in solving some of the key issues that plague the majority of the population. This collaboration aligns with our commitment to finding innovative solutions that positively impact patients' lives and society. We look forward to working closely with the startup community to drive meaningful change," said Sandip Agarwal, Interim Managing Director, Boehringer Ingelheim India.

"We are pleased to partner with Boehringer Ingelheim India, a global leader in pharma innovation, in our mission to support socially impactful innovations. This Memorandum of Understanding is a testament to the power of collaboration between academia and industry in driving innovation and creating positive social impact. With this partnership, we aim to leverage our collective expertise and resources to nurture and promote innovative ideas that can bring about significant societal changes," said Professor Abhay Karandikar, Director of IIT Kanpur.

Speaking on this collaboration, Prof. Ankush Sharma, Professor–in–Charge, SIIC, IIT Kanpur, said, "We are thrilled to announce our association with Boehringer Ingelheim India, a renowned player in the pharmaceutical industry, to promote socially impactful innovations. This association is a significant stride in our shared objective of supporting socially impactful startups that can transfer positive change to society. With this collaboration, we aim to create a conducive environment for young innovators to turn their ideas into successful ventures. Our partnership is assumed to harness the synergies of our respective capabilities, culminating in new and pioneering ideas that can spur economic progress in India.”

Read also: Boehringer Ingelheim gets CDSCO panel nod to market Spesolimab indicated for generalized pustular psoriasis